Target Name: CCZ1B
NCBI ID: G221960
Review Report on CCZ1B Target / Biomarker Content of Review Report on CCZ1B Target / Biomarker
CCZ1B
Other Name(s): CCZ1 vacuolar protein trafficking and biogenesis associated B | C7orf28B | H_DJ1163J12.2 | CCZ1 homolog B, vacuolar protein trafficking and biogenesis associated | Vacuolar fusion protein CCZ1 homolog B | CCZ1 vacuolar protein trafficking and biogenesis associated homolog B (S. cerevisiae) | Vacuolar fusion protein CCZ1 homolog | H_NH0577018.2 | CCZ1 | vacuolar fusion protein CCZ1 homolog B | C7orf28A | CCZ1 vacuolar protein trafficking and biogenesis associated homolog B | CCZ1 homolog, vacuolar protein trafficking and biogenesis associated B | CCZ1_HUMAN

CCZ1B: A Potential Drug Target and Biomarker for Vaccine Development and Antiviral Therapies

Abstract:

CCZ1B (CCZ1 vacuolar protein trafficking and biogenesis associated B) is a protein that has been identified as a potential drug target and biomarker for vaccine development and antiviral therapies. Its functions in vacuolar protein trafficking and biogenesis have been extensively studied, providing insights into the underlying mechanisms of these processes. In this article, we will summarize the current understanding of CCZ1B, its potential drug targeting implications, and its role as a biomarker in the development of vaccines and antiviral therapies.

Introduction:

Vaccines have long been a cornerstone of preventive healthcare, and the development of effective and safe vaccines remains a major challenge. The vacuolar system plays a critical role in the production and delivery of vaccines, as it provides a framework for the formation of intracellular granules that contain antigens. One of the key proteins involved in this process is CCZ1B (CCZ1 vacuolar protein trafficking and biogenesis associated B).

CCZ1B is a 26 kDa protein that is expressed in a variety of tissues, including the brain, spleen, and Peyer's patches of the intestine. It is primarily localized to the endoplasmic reticulum (ER), where it is involved in the trafficking of various proteins to their final destinations. In addition to its role in protein trafficking, CCZ1B has also been shown to be involved in the biogenesis of new proteins, including those involved in vacuolar protein trafficking.

Potential Drug Targets:

The potential drug targeting of CCZ1B is based on its involvement in vacuolar protein trafficking and the production of intracellular granules. Several studies have shown that CCZ1B can interact with various protein partners, including its own protein (CCZ1B-like) and the protein tyrosine phosphatase ( PTP). These interactions may be involved in the regulation of intracellular signaling pathways that are important for the development and maintenance of the vacuolar system.

In addition to its role in protein trafficking, CCZ1B has also been shown to play a key role in the production of intracellular granules. granules are small organelles that form the endoplasmic reticulum and are involved in the delivery of various proteins to their final destinations. Studies have shown that CCZ1B is involved in the formation and stability of granules, and that its absence or inhibition can disrupt the formation of these organelles.

Biomarkers:

The potential use of CCZ1B as a biomarker for vaccine development and antiviral therapies is based on its involvement in the production and delivery of proteins involved in these processes. Studies have shown that CCZ1B is involved in the production of proteins involved in the immune response, including antibodies and T cells. In addition, CCZ1B has also been shown to play a key role in the production of proteins involved in the production of viral vaccines, including Ad neutralizing T cells.

Conclusion:

In conclusion, CCZ1B is a protein that has significant functions in vacuolar protein trafficking and biogenesis, and its potential as a drug target and biomarker for vaccine development and antiviral therapies is based on its involvement in these processes. Further research is needed to fully understand the role of CCZ1B in the development and maintenance of the vacuolar system, and to explore its potential as a drug target and biomarker.

Protein Name: CCZ1 Homolog B, Vacuolar Protein Trafficking And Biogenesis Associated

The "CCZ1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCZ1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2